{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,5]],"date-time":"2026-06-05T21:41:54Z","timestamp":1780695714075,"version":"3.54.1"},"reference-count":40,"publisher":"Wiley","issue":"3","license":[{"start":{"date-parts":[[2023,10,11]],"date-time":"2023-10-11T00:00:00Z","timestamp":1696982400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["European J of Haematology"],"published-print":{"date-parts":[[2024,3]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Novel therapies for multiple myeloma (MM) have improved patient survival, but their high costs strain healthcare budgets. End\u2010of\u2010life phases of treatment are generally the most expensive, however, these high costs may be less justifiable in the context of a less pronounced clinical benefit. To manage drug expenses effectively, detailed information on end\u2010of\u2010life drug administration and costs are crucial. In this retrospective study, we analysed treatment sequences and drug costs from 96\u2009MM patients in the Netherlands who died between January 2017 and July 2019. Patients received up to 16 lines of therapy (median overall survival: 56.5\u2009months), with average lifetime costs of \u20ac209\u2009871 (\u20ac3111\/month; range: \u20ac3942\u2013\u20ac776\u2009185) for anti\u2010MM drugs. About 85% of patients received anti\u2010MM treatment in the last 3\u2009months before death, incurring costs of \u20ac20\u2009761 (range: \u20ac70\u2013\u20ac50\u2009122; 10% of total). Half of the patients received anti\u2010MM treatment in the last 14\u2009days, mainly fully oral regimens (66%). End\u2010of\u2010life treatment costs are substantial despite limited survival benefits. The use of expensive treatment options is expected to increase costs further. These data serve as a reference point for future cost studies, and further research is needed to identify factors predicting the efficacy and clinical benefit of continuing end\u2010of\u2010life therapy.<\/jats:p>","DOI":"10.1111\/ejh.14119","type":"journal-article","created":{"date-parts":[[2023,10,12]],"date-time":"2023-10-12T06:06:20Z","timestamp":1697090780000},"page":"360-366","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Treatment sequences and drug costs from diagnosis to death in multiple myeloma"],"prefix":"10.1111","volume":"112","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0824-0354","authenticated-orcid":false,"given":"M. R.","family":"Seefat","sequence":"first","affiliation":[{"name":"Department of Hematology Amsterdam University Medical Centers, Vrije Universiteit Amsterdam, Cancer Center Amsterdam  Amsterdam The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6706-5464","authenticated-orcid":false,"given":"D. G. J.","family":"Cucchi","sequence":"additional","affiliation":[{"name":"Department of Hematology Amsterdam University Medical Centers, Vrije Universiteit Amsterdam, Cancer Center Amsterdam  Amsterdam The Netherlands"},{"name":"Department of Internal Medicine Franciscus Gasthuis &amp; Vlietland  Rotterdam The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K.","family":"Groen","sequence":"additional","affiliation":[{"name":"Department of Hematology Amsterdam University Medical Centers, Vrije Universiteit Amsterdam, Cancer Center Amsterdam  Amsterdam The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M. L.","family":"Donker","sequence":"additional","affiliation":[{"name":"Department of Hematology Amsterdam University Medical Centers, Vrije Universiteit Amsterdam, Cancer Center Amsterdam  Amsterdam The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K. G.","family":"van der Hem","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine Zaandam Medical Center  Zaandam The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Westerman","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine Northwest Clinics  Alkmaar The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A. M.","family":"Gerrits","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine OLVG  Amsterdam The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Beeker","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine Spaarne Gasthuis  Hoofddorp The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7445-2603","authenticated-orcid":false,"given":"N. W. C. J.","family":"van de Donk","sequence":"additional","affiliation":[{"name":"Department of Hematology Amsterdam University Medical Centers, Vrije Universiteit Amsterdam, Cancer Center Amsterdam  Amsterdam The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5846-0531","authenticated-orcid":false,"given":"H. M.","family":"Blommestein","sequence":"additional","affiliation":[{"name":"Erasmus School of Health Policy and Management Erasmus University Rotterdam  Rotterdam The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5011-1820","authenticated-orcid":false,"given":"S.","family":"Zweegman","sequence":"additional","affiliation":[{"name":"Department of Hematology Amsterdam University Medical Centers, Vrije Universiteit Amsterdam, Cancer Center Amsterdam  Amsterdam The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2023,10,11]]},"reference":[{"key":"e_1_2_11_2_1","doi-asserted-by":"publisher","DOI":"10.1080\/13696998.2022.2133823"},{"key":"e_1_2_11_3_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(21)00135-5"},{"key":"e_1_2_11_4_1","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2016.380"},{"key":"e_1_2_11_5_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2007-10-116129"},{"key":"e_1_2_11_6_1","doi-asserted-by":"publisher","DOI":"10.1080\/10428194.2020.1827253"},{"key":"e_1_2_11_7_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40487-022-00198-0"},{"key":"e_1_2_11_8_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2022.17825"},{"key":"e_1_2_11_9_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40273-020-00993-5"},{"key":"e_1_2_11_10_1","doi-asserted-by":"publisher","DOI":"10.3390\/cancers13225606"},{"key":"e_1_2_11_11_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2021.16357"},{"key":"e_1_2_11_12_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-016-2835-7"},{"issue":"1","key":"e_1_2_11_13_1","first-page":"39","article-title":"Temporal trends in survival and healthcare costs in patients with multiple myeloma in the United States","volume":"11","author":"Maiese EM","year":"2018","journal-title":"Am Health Drug Benefits"},{"key":"e_1_2_11_14_1","doi-asserted-by":"publisher","DOI":"10.1200\/EDBK_238527"},{"key":"e_1_2_11_15_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2016.69.2517"},{"key":"e_1_2_11_16_1","doi-asserted-by":"publisher","DOI":"10.1182\/asheducation-2017.1.498"},{"key":"e_1_2_11_17_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12904-017-0213-0"},{"key":"e_1_2_11_18_1","doi-asserted-by":"publisher","DOI":"10.1200\/JOP.2011.000469"},{"key":"e_1_2_11_19_1","doi-asserted-by":"publisher","DOI":"10.1002\/hec.1597"},{"key":"e_1_2_11_20_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-021-08079-x"},{"key":"e_1_2_11_21_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.14213"},{"key":"e_1_2_11_22_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.clml.2018.08.019"},{"key":"e_1_2_11_23_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.clml.2020.10.002"},{"key":"e_1_2_11_24_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.18401"},{"key":"e_1_2_11_25_1","doi-asserted-by":"publisher","DOI":"10.1097\/HS9.0000000000000913"},{"key":"e_1_2_11_26_1","doi-asserted-by":"publisher","DOI":"10.1200\/EDBK_159009"},{"key":"e_1_2_11_27_1","unstructured":"Z\u2010index.G\u2010standaard medicijnkosten (8\u20102020). Z\u2010Indexnl.2020."},{"key":"e_1_2_11_28_1","unstructured":"Nederlands Zorginstituut (Dutch Healthcare Institute).Guideline for economic evaluations in healthcare.2016https:\/\/english.zorginstituutnederland.nl\/publications\/reports\/2016\/06\/16\/guideline-for-economic-evaluations-in-healthcare"},{"key":"e_1_2_11_29_1","volume-title":"Methods for the Economic Evaluation of Health Care Programmes","author":"Drummond MF","year":"2015"},{"key":"e_1_2_11_30_1","unstructured":"International Monetary Fund.SDRs per Currency Unit for March 2023.2023https:\/\/www.imf.org\/external\/np\/fin\/data\/rms_mth.aspx?SelectDate=2023-03-31&reportType=SDRCV"},{"key":"e_1_2_11_31_1","doi-asserted-by":"publisher","DOI":"10.1177\/10732748221142945"},{"key":"e_1_2_11_32_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2203478"},{"key":"e_1_2_11_33_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3026(22)00226-5"},{"key":"e_1_2_11_34_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2204591"},{"key":"e_1_2_11_35_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00520-013-1991-4"},{"key":"e_1_2_11_36_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.clml.2023.03.005"},{"key":"e_1_2_11_37_1","doi-asserted-by":"publisher","DOI":"10.1097\/HS9.0000000000000045"},{"key":"e_1_2_11_38_1","doi-asserted-by":"publisher","DOI":"10.1177\/0269216315601346"},{"key":"e_1_2_11_39_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.sapharm.2018.03.064"},{"key":"e_1_2_11_40_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.18324"},{"key":"e_1_2_11_41_1","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.24796"}],"container-title":["European Journal of Haematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/ejh.14119","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,16]],"date-time":"2024-02-16T02:27:07Z","timestamp":1708050427000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/ejh.14119"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,10,11]]},"references-count":40,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2024,3]]}},"alternative-id":["10.1111\/ejh.14119"],"URL":"https:\/\/doi.org\/10.1111\/ejh.14119","archive":["Portico"],"relation":{},"ISSN":["0902-4441","1600-0609"],"issn-type":[{"value":"0902-4441","type":"print"},{"value":"1600-0609","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,10,11]]},"assertion":[{"value":"2023-06-29","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-09-30","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-10-11","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}